Thrombotic disease in the myeloproliferative neoplasms

Falanga A, Marchetti M.

Hematology Am Soc Hematol Educ Program. 2012;2012:571-81

Venous thromboembolism in the hematologic malignancies

Falanga A, Marchetti M, Russo L.

Curr Opin Oncol. 2012 Nov;24(6):702-10

Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival

Falanga A, Vignoli A, Diani E, Marchetti M.

Patient Relat Outcome Meas. 2011 Jul;2:175-88

6th International Conference on Thrombosis and Hemostasis Issues in Cancer. Preface

Falanga A, Brenner B, Rickles FR.

Thromb Res. 2012 Apr;129 Suppl 1:ix.

Microparticles in tumor progression

Falanga A, Tartari CJ, Marchetti M.

Thromb Res. 2012 Apr;129 Suppl 1:S132-6.

Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography

Marchetti M, Diani E, ten Cate H, Falanga A.

Haematologica. 2012 Aug;97(8):1173-80.

Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies

Dienava-Verdoold I, Marchetti MR, te Boome LC, Russo L, Falanga A, Koene HR, Mertens K, Brinkman HJ.

Thromb Haemost. 2012 Mar;107(3):468-76.

Anticancer treatment and thrombosis

Falanga A, Marchetti M.

Thromb Res. 2012; 129(3):353-9.

Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines

Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2011;22 Suppl 6:vi85-92

Epidemiology, risk and outcomes of venous thromboembolism in cancer

Falanga A, Russo L.

Hamostaseologie. 2012;32(2):115-25.

Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1).

Siragusa S, Armani U, Carpenedo M, Falanga A, Fulfaro F, Imberti D, Laurora R, Molinari AC, Prisco D, Silingardi M, Verso M, Visonà A; Italian Society for Haemostasis and Thrombosis.

Thromb Res. 2012;129(5):e171-6.